Hutchmed China Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Hutchmed China Limited (HCM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Hutchmed China Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 549M vs 181,057M combined for tracked competitors (0.3% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+93.8%) for its tracked peer group.
- Growth: Hutchmed China Limited generated -13.0% revenue growth year over year in Q4 2025, vs 7.9% for its tracked competitors combined.
- Profitability: Its 83.5% net margin compares with 19.5% for the peer group.
- Scale: Hutchmed China Limited ranks #33 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.2% of industry market cap.
- Peer revenue share: Hutchmed China Limited accounted for 0.6% of combined revenue among its tracked peer group, down from 0.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.70M compares with $0.89M for the peer group (0.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
HCM Sales vs. its Competitors, Q4 2025
Hutchmed China Limited reported revenue contraction of 12.96 % year on year in Q4 2025, below its competitors' combined revenue growth of 7.86 %.
With a net margin of 83.45 %, Hutchmed China Limited achieved higher profitability than its competitors (19.46 %).
Hutchmed China Limited generated 0.62 % of the combined sales of its peer group, down from 0.77 % a year earlier.
Hutchmed China Limited vs. its Competitors, Q4 2025
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Hutchmed China Limited and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Hutchmed china Limited | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Hutchmed China Limited's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -13.0% for Hutchmed China Limited. Hutchmed China Limited's share of combined industry revenue moved from 0.09% to 0.07%, a loss of 0.02 percentage points.
Hutchmed China Limited's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Hutchmed china Limited | Yes | No | No | No |
| Competitors combined (100) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 12.50 % (1 of 8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
HCM Stock Performance relative to its Competitors
HCM Stock Performance relative to Similar-Size Competitors
HCM Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 2 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 3 | Rallybio Corporation | 282.9% | Outperformed |
| 4 | Nuvectis Pharma inc | 282.9% | Outperformed |
| 5 | Day One Biopharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Hutchmed China Limited's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Hutchmed China Limited's Comment on Competition and Industry Peers
Publicly Traded Peers of Hutchmed china Limited
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Hutchmed china Limited | 12,333.95 | 548.51 |
| Beone Medicines Ltd | 552,467.82 | 6,128.24 |
| Merck and Co Inc | 367,264.30 | 66,569.00 |
| Novartis Ag | 287,150.40 | 56,674.00 |
| Bristol myers Squibb Company | 130,826.24 | 49,186.00 |
| Zai Lab Limited | 28,695.05 | 449.61 |
| SUBTOTAL | 1,472,863.07 | 182,612.10 |
Sign in to see all competitors of Hutchmed china Limited.
Sources: Hutchmed china Limited's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Hutchmed china Limited versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Hutchmed China Limited's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
| Syndax Pharmaceuticals Inc | Biopharmaceutical Cancer Therapeutics 100.00 % |
| Rigel Pharmaceuticals Inc | One Operating 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Hutchmed china Limited.
Hutchmed China Limited's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Hutchmed china Limited | 12,334 | 703,221 | 586,836 |
| Beone Medicines Ltd | 552,468 | 510,686 | 54,642 |
| Merck and Co Inc | 367,264 | 887,587 | 42,267 |
| Novartis Ag | 287,150 | 752,973 | 185,566 |
| Bristol myers Squibb Company | 130,826 | 1,513,415 | 285,354 |
| Zai Lab Limited | 28,695 | 252,026 | -105,501 |
| PEERS TOTAL | 1,460,529 | 891,306 | 103,113 |
Sign in to see all peers for Hutchmed china Limited.
Hutchmed China Limited's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Hutchmed china Limited | CN 74.28 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Xoma Royalty Corporation | CH 54.36 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Hutchmed china Limited.
Hutchmed China Limited's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Hutchmed China Limited's industry classification, broader than the peer set above. Market cap in millions of $.Hutchmed China Limited ranks #33 of 498 companies by market capitalization in its industry, holding 0.22 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 33 | Hutchmed china Limited | 12,316 | 0.22 % |
Market cap and industry share for the rest of Hutchmed China Limited's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Hutchmed China Limited's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 28 | Jazz Pharmaceuticals Plc | 16,402 | 84.93 % |
| 29 | Madrigal Pharmaceuticals Inc | 14,772 | 19.82 % |
| 30 | Ascendis Pharma A | 13,669 | 18.86 % |
| 31 | Corcept Therapeutics Inc | 13,646 | 39.33 % |
| 32 | Bridgebio Pharma Inc | 1,234 | 12.3% |
| 33 | Hutchmed china Limited | 12,316 | -10.64 % |
| 34 | Summit Therapeutics Inc | 1,234 | 12.3% |
| 35 | Biomarin Pharmaceutical Inc | 1,234 | 12.3% |
| 36 | Elanco Animal Health Incorporated | 1,234 | 12.3% |
| 37 | Dr Reddy s Laboratories Limited | 1,234 | 12.3% |
| 38 | Axsome Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Hutchmed China Limited's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Hutchmed China Limited's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 38.68 % | 64.89 % (avg) | -26.2 pp |
| Operating Margin | -7.14 % | industry median | +22.2 pp |
| EBITDA Margin | 93.10 % | -7.21 % (avg) | +100.3 pp |
| Capital Intensity (Capex / Revenue) | 1.82 % | 4.92 % (avg) | -3.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Hutchmed China Limited's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 28.1x | 25.1x | +3.0x |
| EV / EBITDA | 25.1x | 17.3x | +7.8x |
| P/B | 10.3x | 4.5x | +5.8x |
| Return on Equity | 36.98 % | industry aggregate | 10.73 % |
| Return on Invested Capital | -1.44 % | -2.95 % (avg) | 1.51 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Hutchmed China Limited's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | 96.52 % | -24.80 % | -12.96 % |
| Operating Margin | 2.19 % | -6.94 % | -7.14 % |
| Return on Invested Capital | 1.10 % | -2.60 % | -1.44 % |
| P/E | 151.5x | 446.6x | 28.1x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Hutchmed China Limited's Strategic Group Map
Every company in Hutchmed China Limited's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Hutchmed China Limited is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Hutchmed China Limited's BCG Growth-Share Matrix
Relative market share (vs Hutchmed China Limited's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Hutchmed China Limited falls in the Dog quadrant: relative market share of 0.01x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Hutchmed China Limited's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.82 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Hutchmed China Limited's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Hutchmed China Limited's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Hutchmed China Limited's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Hutchmed China Limited falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Hutchmed China Limited's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 22.2 points above the industry median.
- Return on equity 10.7 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.01x).
Opportunities
- A meaningful share of tracked competitors (51.70 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Hutchmed China Limited's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Hutchmed china Limited | 0.23 | 4.96 | 0.10 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Zai Lab Limited | 1.66 | 2.45 | 0.31 |
Sign in to see all peers for Hutchmed china Limited.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Hutchmed China Limited's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Hutchmed china Limited | Q4 2025 | -13.0 % | +1,099.2 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Zai Lab Limited | Q2 2026 | -3.3 % | - |
| PEERS TOTAL | +8.6 % | -4.5 % |
Sign in to see all peers for Hutchmed china Limited.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Hutchmed China Limited's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Hutchmed china Limited | Q4 2025 | -3.6 % | -44.2 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Zai Lab Limited | Q2 2026 | +12.0 % | -53.5 % |
Sign in to see all peers for Hutchmed china Limited.
Hutchmed China Limited's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Hutchmed china Limited | 26.11% | 30.87% | 36.98% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Zai Lab Limited | - | - | - |
Sign in to see all peers for Hutchmed china Limited.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Hutchmed China Limited's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Hutchmed china Limited | 27.17 | 22.49 |
| Beone Medicines Ltd | 834.09 | 90.15 |
| Merck and Co Inc | 119.91 | 5.52 |
| Novartis Ag | 20.53 | 5.07 |
| Bristol myers Squibb Company | 14.06 | 2.66 |
| Zai Lab Limited | - | 63.82 |
| PEERS AVERAGE | 68.44 | 8.07 |
Sign in to see all peers for Hutchmed china Limited.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.